IP Library Granted Patent US 7,101,718
Granted Patent B2
US 7,101,718 · App. 10/918,622 · Granted Sep 5, 2006

Organo luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,101,718
App. No.
10/918,622
Granted
Sep 5, 2006
Kind
B2
Abstract

A semiconductor nanocrystal compound is described capable of linking to an affinity molecule. The compound comprises (1) a semiconductor nanocrystal capable of emitting electromagnetic radiation and/or absorbing energy, and/or scattering or diffracting electromagnetic radiation—when excited by an electromagnetic radiation source or a particle beam; and (2) at least one linking agent, having a first portion linked to the semiconductor nanocrystal and a second portion capable of linking to an affinity molecule. The compound is linked to an affinity molecule to form a semiconductor nanocrystal probe capable of bonding with a detectable substance. subsequent exposure to excitation energy will excite the semiconductor nanocrystal in the probe causing the emission of electromagnetic radiation. Further described are processes for respectively: making the luminescent semiconductor nanocrystal compound; making the semiconductor nanocrystal probe; and using the probe to determine the presence of a detectable substance in a material.

Claims (38)

1. A composition, comprising:

a semiconductor nanocrystal which emits light when excited;

a polymerizable linking agent;

an affinity molecule linked to the linking agent; and

a detectable substance bound to the affinity molecule.

2. The composition as claimed in claim 1 , wherein the polymerizable linking agent encapsulates the semiconductor nanocrystal.

3. The composition as claimed in claim 1 , further comprising a first additional semiconductor nanocrystal which emits light when excited.

4. The composition as claimed in claim 1 , further comprising:

a plurality of additional semiconductor nanocrystals which emit light when excited.

5. A composition, comprising:

a plurality of semiconductor nanocrystals which emit light when excited;

a polymerizable linking agent encapsulating the nanocrystals;

an affinity molecule linked to the linking agent; and

a detectable substance bound to the affinity molecule.

6. The composition as claimed in claim 5 wherein the linking agent is comprised of a polymer and chosen from diacetylenes, acrylates, acrylamides, vinyl, and styryl.

7. A composition, comprising:

a semiconductor nanocrystal which emits light when excited;

an affinity molecule; and

a detectable substance bound to the affinity molecule.

8. The composition as claimed in claim 7 , further comprising a polymer wherein the polymer encapsulates the semiconductor nanocrystal.

9. The composition as claimed in claim 8 , further comprising a first additional semiconductor nanocrystal which emits light when excited.

10. The composition as claimed in claim 9 , further comprising:

a plurality of additional semiconductor nanocrystals which emit light when excited.

11. A composition, comprising:

a plurality of semiconductor nanocrystals which emit light when excited;

an affinity molecule; and

a detectable substance bound to the affinity molecule.

12. The composition of claims 11 , wherein the plurality of semiconductor nanocrystals comprise nanocrystals which emit a distinct wavelength of light different from that emitted by other semiconductor nanocrystals.

13. The composition of claim 11 , wherein the affinity molecule is a biological material.

14. The composition of claim 11 , wherein the affinity molecule is an antibody chosen from a monoclonal antibody and a polyclonal antibody.

15. The composition of claim 11 , wherein the affinity molecule is a nucleic acid.

16. The composition of claim 15 , wherein the nucleic acid is monomeric.

17. The composition of claim 15 , wherein the nucleic acid is oligomeric.

18. The composition of claim 11 , wherein the affinity molecule is a protein.

19. The composition of claim 11 , wherein the affinity molecule is a polysaccharide.

20. The composition of claim 11 , wherein the affinity molecule is a sugar.

21. The composition of claim 11 , wherein the affinity molecule is a peptide.

22. The composition of claim 11 , wherein the affinity molecule is a drug.

Assignments (3)
CONFIRMATORY LICENSE Recorded Feb 26, 2007
From: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
To: UNITED STATES DEPARTMENT OF ENERGY
Reel/Frame 018936/0299 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2005
From: WEISS, SHIMON; BRUCHEZ JR., MARCEL; ALIVISATOS, PAUL
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 016600/0431 →
SECURITY AGREEMENT Recorded Feb 16, 2005
From: QUANTUM DOT CORPORATION
To: INSTITUTIONAL VENTURE PARTNERS VII, L.P.; INSTITUTIONAL VENTURE MANAGEMENT VII, L.P.; ABINGWORTH BIOVENTURES IIA LP; SCHRODER VENTURES INTERNATIONAL LIFE SCIENCES FUND II LP1; SCHRODER VENTURES INTERNATIONAL LIFE SCIENCES FUND II LP2; SCHRODER VENTURES INTERNATIONAL LIFE SCIENCES FUND II LP3; SV NOMINEES LIMITED ON BEHALF OF SCHRODER VENTURES INVESTMENTS LIMITED; SCHRODER VENTURES INTERNATIONAL LIFE SCIENCES FUND II GROUP CO-INVESTMENT SCHEME; SCHRODER VENTURES INTERNATIONAL LIFE SCIENCES FUND II STRATEGIC PARTNERS LP; FRAZIER HEALTHCARE III, L.P.; FRAZIER AFFILIATES III, L.P.; BB BIOVENTURES L.P.; MPM ASSET MANAGEMENT INVESTORS 2000 A LLC; MPM BIOVENTURES PARALLEL FUND, L.P.
Reel/Frame 015687/0106 →